TY - JOUR
T1 - Ex vivo lung perfusion
T2 - how we do it
AU - Murala, John Santosh
AU - Whited, William Michael
AU - Banga, Amit
AU - Castillo, Robert
AU - Peltz, Matthias
AU - Huffman, Lynn Custer
AU - Hackmann, Amy Elizabeth
AU - Jessen, Michael Erik
AU - Torres, Fernando
AU - Wait, Michael Alton
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/9
Y1 - 2021/9
N2 - Lung transplantation is an established treatment for patients with end-stage lung disease. However, a shortage of donors, low lung utilization among potential donors, and waitlist mortality continue to be challenges. In the last decade, ex vivo lung perfusion (EVLP) has expanded the donor pool by allowing prolonged evaluation of marginal donor lungs and allowing reparative therapies for lungs, which are otherwise considered not transplantable. In this review, we describe in detail our experience with EVLP including our workflow, setup, operative technique, and protocols. Our multidisciplinary EVLP program functions with the collaboration of surgeons, pulmonologists, and EVLP nurses who run the pump. EVLP program has been a valuable addition to our program. Since Food and Drug Administration (FDA) approval in 2019, we experienced incremental increased lung transplant volume of 12% annually.
AB - Lung transplantation is an established treatment for patients with end-stage lung disease. However, a shortage of donors, low lung utilization among potential donors, and waitlist mortality continue to be challenges. In the last decade, ex vivo lung perfusion (EVLP) has expanded the donor pool by allowing prolonged evaluation of marginal donor lungs and allowing reparative therapies for lungs, which are otherwise considered not transplantable. In this review, we describe in detail our experience with EVLP including our workflow, setup, operative technique, and protocols. Our multidisciplinary EVLP program functions with the collaboration of surgeons, pulmonologists, and EVLP nurses who run the pump. EVLP program has been a valuable addition to our program. Since Food and Drug Administration (FDA) approval in 2019, we experienced incremental increased lung transplant volume of 12% annually.
KW - Donor selection
KW - Ex vivo lung perfusion
KW - Lung transplantation
UR - http://www.scopus.com/inward/record.url?scp=85114033239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114033239&partnerID=8YFLogxK
U2 - 10.1007/s12055-021-01215-z
DO - 10.1007/s12055-021-01215-z
M3 - Review article
C2 - 34483507
AN - SCOPUS:85114033239
SN - 0970-9134
VL - 37
SP - 433
EP - 444
JO - Indian Journal of Thoracic and Cardiovascular Surgery
JF - Indian Journal of Thoracic and Cardiovascular Surgery
ER -